Assessing Adverse Events From BOVen Therapy in Patients With Previously Untreated CLL

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses the adverse events experienced by patients with previously untreated chronic lymphocytic leukemia when treated with zanubrutinib, obinutuzumab, and venetoclax.

Pharmacy Times interviewed Jacob D. Soumerai, MD, assistant professor, medicine at Harvard Medical School and a clinical investigator in lymphoma, medicine at Massachusetts General Hospital, on his recent presentation at the American Society of Hematology Annual Meeting and Exposition 2021 on minimum residual disease-driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated chronic lymphocytic leukemia (CLL).

During this discussion, Soumerai goes over the adverse events experienced by patients with previously untreated CLL when treated with BOVen.